Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (3115)	3/16/2001 4:01:41 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

reverting to an earlier era where every biotech but the profitable ones remained at best a cut above penny stock status and were driven to MA activities to survive -- selling out to large pharmas or merging with each other for protection. I think there are a few reasons why things (I hope) are different now. First, biotechs gobbled up between $20 and $30 billion during the bubble. That's a substantial cash cushion that didn't use to be there. Second, the "terms of trade" between the pharma and the biotechs have changed substantially. What used to be 10% royalties (or even less) are suddenly 50:50 partnerships. Third, there are many more biotechs that are in sight of profitability. I do agree that the weaker biotechs will get swallowed up (assuming they have decent programs, that is). On a macro level, I grant things are pretty scary for the economy right now. Today's PPI had more than a whiff of deflation. Even at these depressed prices, I hardly see a stock like INTC as a bargain - it still sports a PE well above what a cyclical producer of a commoditized product deserves. I'm not sure that CSCO is any better, although I don't understand that market as well. I recall doing a comparison of AMGN and CSCO (earnings, R&D expense, growth rate, PE) on this thread a while back. If I can locate it and have the time, an update would be interesting. Personally, I moved some money into Treasuries today. Despite the biotech bargains on offer things are looking increasingly jittery out there. Peter